Calithera Biosciences Inc (NASDAQ:CALA) – Analysts at William Blair issued their FY2022 earnings per share estimates for shares of Calithera Biosciences in a research note issued to investors on Tuesday. William Blair analyst M. Phipps anticipates that the biotechnology company will post earnings of $0.80 per share for the year.
Calithera Biosciences (NASDAQ:CALA) last announced its quarterly earnings results on Thursday, November 2nd. The biotechnology company reported ($0.17) EPS for the quarter, topping the consensus estimate of ($0.23) by $0.06. The company had revenue of $7.20 million during the quarter, compared to analysts’ expectations of $6.02 million.
Shares of Calithera Biosciences (CALA) traded down $0.25 during midday trading on Wednesday, hitting $7.45. 518,465 shares of the stock traded hands, compared to its average volume of 442,372. The stock has a market cap of $264.30, a PE ratio of -7.53 and a beta of 2.56. Calithera Biosciences has a 52-week low of $6.75 and a 52-week high of $20.05.
A number of institutional investors have recently bought and sold shares of CALA. Schwab Charles Investment Management Inc. raised its position in Calithera Biosciences by 249.3% in the 2nd quarter. Schwab Charles Investment Management Inc. now owns 71,600 shares of the biotechnology company’s stock worth $1,064,000 after purchasing an additional 51,100 shares during the period. Bank of New York Mellon Corp raised its position in Calithera Biosciences by 230.7% in the 2nd quarter. Bank of New York Mellon Corp now owns 108,102 shares of the biotechnology company’s stock worth $1,605,000 after purchasing an additional 75,414 shares during the period. Legal & General Group Plc purchased a new stake in Calithera Biosciences in the 2nd quarter worth about $120,000. Wells Fargo & Company MN grew its stake in Calithera Biosciences by 705.3% in the 2nd quarter. Wells Fargo & Company MN now owns 26,832 shares of the biotechnology company’s stock worth $399,000 after acquiring an additional 23,500 shares in the last quarter. Finally, Alliancebernstein L.P. bought a new position in Calithera Biosciences in the 2nd quarter worth about $899,000. 72.54% of the stock is currently owned by institutional investors.
ILLEGAL ACTIVITY NOTICE: “Analysts Issue Forecasts for Calithera Biosciences Inc’s FY2022 Earnings (CALA)” was published by American Banking News and is owned by of American Banking News. If you are reading this news story on another domain, it was copied illegally and republished in violation of US & international copyright and trademark law. The correct version of this news story can be viewed at https://www.americanbankingnews.com/2018/02/07/analysts-issue-forecasts-for-calithera-biosciences-incs-fy2022-earnings-cala.html.
Calithera Biosciences Company Profile
Calithera Biosciences, Inc is a clinical-stage pharmaceutical company. The Company focuses on discovering and developing small molecule drugs directed against tumor and immune cell targets that control key metabolic pathways in the tumor microenvironment. It is engaged in developing agents that take advantage of the metabolic requirements of tumor cells and cancer-fighting immune cells, such as cytotoxic T-cells.
Receive News & Ratings for Calithera Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Calithera Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.